Evidence map›Paper›PMID 33579303›Full record

ArticleJournal of nanobiotechnology2021

Novel fusion peptide-mediated siRNA delivery using self-assembled nanocomplex.

Yeong Chae Ryu, Kyung Ah Kim, Byoung Choul Kim, Hui-Min David Wang, Byeong Hee Hwang

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yeong Chae RyuDepartment of Bioengineering and Nano-bioengineering, Incheon National University, Academy-ro 119, Yeonsu-gu, Incheon, 22012, Korea.
Kyung Ah KimDepartment of Bioengineering and Nano-bioengineering, Incheon National University, Academy-ro 119, Yeonsu-gu, Incheon, 22012, Korea.
Byoung Choul KimDepartment of Bioengineering and Nano-bioengineering, Incheon National University, Academy-ro 119, Yeonsu-gu, Incheon, 22012, Korea.
Hui-Min David WangGraduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung, 402, Taiwan.
Byeong Hee HwangDepartment of Bioengineering and Nano-bioengineering, Incheon National University, Academy-ro 119, Yeonsu-gu, Incheon, 22012, Korea. bhwang@inu.ac.kr.ORCID http://orcid.org/0000-0003-1349-6351
Incheon National University · KRNational Chung Hsing University · TW

Funding

National Research Foundation of Korea NRF-2019R1F1A1063316
6 · The paper itself

Abstract

backgroundGene silencing using siRNA can be a new potent strategy to treat many incurable diseases at the genetic level, including cancer and viral infections. Treatments using siRNA essentially requires an efficient and safe method of delivering siRNA into cells while maintaining its stability. Thus, we designed novel synergistic fusion peptides, i.e., SPACE and oligoarginine.

resultsAmong the novel fusion peptides and siRNAs, nanocomplexes have enhanced cellular uptake and gene silencing effect in vitro and improved retention and gene silencing effects of siRNAs in vivo. Oligoarginine could attract siRNAs electrostatically to form stable and self-assembled nanocomplexes, and the SPACE peptide could interact with the cellular membrane via hydrogen bonding. Therefore, nanocomplexes using fusion peptides showed improved and evident cellular uptake and gene silencing of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) via the lipid raft-mediated endocytosis pathway, especially to the HDFn cells of the skin, and all of the fusion peptides were biocompatible. Also, intratumorally injected nanocomplexes had increased retention time of siRNAs at the site of the tumor. Finally, nanocomplexes demonstrated significant in vivo gene silencing effect without overt tissue damage and immune cell infiltration.

conclusionsThe new nanocomplex strategy could become a safe and efficient platform for the delivery of siRNAs into cells and tissues to treat various target diseases through gene silencing.

Indexed as

AnimalsAntitubercular AgentsBiocompatible MaterialsCell SurvivalGene SilencingGlyceraldehyde-3-Phosphate DehydrogenasesHeLa CellsHumansMicePeptide FragmentsPeptidesRNA, Small InterferingStatic ElectricityAntitubercular AgentsBiocompatible Materialsglyceraldehyde 3-phosphate dehydrogenase (304-313)Glyceraldehyde-3-Phosphate DehydrogenasesPeptide FragmentsPeptidesRNA, Small InterferingDrug deliveryGene silencingNanocomplexPeptidesSelf‐assemblysiRNA

Identifiers

PMID33579303
PMCPMC7881583
OpenAlexW3128794291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.